Navigation Links
Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Date:6/18/2013

> has the rights to develop and commercialise safinamide in Japan and other key Asian territories. Newron's additional projects are primarily addressed towards highly promising treatments for rare diseases and are at various stages of preclinical and clinical development, including sNN0031 for Parkinson's disease, sarizotan for Rett's syndrome, sNN0029 for ALS, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia. http://www.newron.com

About Zambon

Zambon is a leading Italian pharmaceutical and fine-chemical multinational company, that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and woman care, and is very strongly committed to its entry into the CNS space. Zambon SpA produces high quality products thanks to the management of the whole production chain which involves Zach (Zambon chemical), a privileged partner for API, custom synthesis and generic products. The Group is strongly working on the treatment of the chronic respiratory diseases as BPCO and on the CNS therapeutic area with safinamide for the Parkinson treatment. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 15 countries with more than 2,600 employees with manufacturing units in Italy, Switzerland, France, China and Brazil.  For details on Zambon please see: http://www.zambongroup.com

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current
'/>"/>

SOURCE Newron Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
3. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
4. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
5. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
6. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
9. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... -- Hovione today announced that its API plant ... a pre-approval inspection by the US Food and Drug Administration ... Consumer Safety Officer, Ms. Britanny Terhar , lasted 5 ... and concluded on the 25 th . The inspection confirmed ... of Good Manufacturing Practices (GMP) and no Form 483 observations ...
(Date:7/31/2014)... NEW YORK and VIENNA , ... today at a press conference in New York ... of PD01A, a vaccine against Parkinson,s disease. PD01A is the ... target, to enter clinical testing. The Michael J. ... a $ 1.5 million grant, and presented at the press ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... April 21, 2011 iMD Companies (ICBU.PK) is pleased ... Testing Facility (IDTF), Optimum Mobile Imaging LLC, which increases ...  The acquisition was done with cash and restricted stock ... can be found at www.OMIAZ.com .   OMI ...
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, ... today the Company,s attendance at the upcoming International Society ... 26 – 29, 2011.  The meeting will be held ... / Palazzo Hotels in Las Vegas, Nevada.   ...
Cached Medicine Technology:iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 2iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 3MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting 2
(Date:7/31/2014)... 31, 2014 Leelanau Peninsula’s newest winery, ... 2014 at 7788 East Horn Road in Lake Leelanau. Joining ... , Aurora Cellars is the 25th winery along the trail. ... popular wine tour events, making its trail event debut during ... , Owners David and Faye Mathia opened the boutique ...
(Date:7/31/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:7/31/2014)... has announced that they are now offering a new ... Review of Sexual Satisfaction . The course is ... Clinical and Health Psychology. , This CE course has ... accurate information about sexual satisfaction so that healthcare professionals ... provides a systematic review of 197 research publications in ...
(Date:7/31/2014)... July 31, 2014 In many states and ... for proper storage of necessary life saving drugs. This requirement ... there is still a high number of ambulances without proper ... who steals the narcotics and even replaces the vital pain ... none. As seen in the case in Baraboo, Wisconsin last ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... In a comparison of anticoagulants and stents for use ... and tirofiban had similar outcomes for some cardiac measures ... received stents that released the drug sirolimus had a ... months than patients who received uncoated stents, according to ...
... March 29 The second annual,National Walk for ... and raised $1.5 million to help build awareness ... to raise much-needed funds. The event,was sponsored by ... http://www.newscom.com/cgi-bin/prnh/20080329/17897 ), The stars coming ...
... 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical ... the American College of Cardiology,s 57th Annual Scientific ... Among the most significant presentations are the following: ... Transplant Allograft Vasculopathy , Dr. Jeffrey ...
... room for improvement in balancing seizure control ... and medication-related side ... of the nation,s,largest event dedicated to the epilepsy community, ... in response to a,new national survey uncovering key challenges ...
... Consultancy to Address Circle of Patient Care, ... Mike Marolt, president of St.,Paul-based eq-life(R), announced ... to provide pharmacy operations consulting to,hospital organizations ... a,multi-year agreement with Omaha-based Alegent Health to ...
... Ranks above National Average in Overall Patient Satisfaction and Other ... ... The Hospital Quality Alliance today,released the first Hospital Consumer Assessment of ... care as rated by patients themselves. Hospital for Special Surgery,(HSS) in New ...
Cached Medicine News:Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:National Walk for Epilepsy Brings People and Celebrities Together for Epilepsy 2Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 2Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 3Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 2Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 3Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 4Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 5Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 3Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 2Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 3
For the quantitative in vitro determination of Digoxin in human serum....
For the quantitative in vitro determination of Microalbumin in urine....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: